|
Management Team
RICHARD FULLER, M.D., Ph.D.
Chief Executive Officer
Dr. Fuller was formerly Executive Vice President of Research and Development at Aerovance. He is a Fellow of the Royal College of Physicians and is clinically accredited in Internal Medicine and Clinical Pharmacology. Following a career in Clinical and Academic Medicine and publishing widely on asthma, inflammation and cough he joined Glaxo (now GlaxoSmithKline (GSK)) as head of the Respiratory Clinical group. He had several head positions within GSK, including the Respiratory Therapeutic to manage both the development matrix and the central clinical and commercial activities. Subsequent to his position in GSK, Dr. Fuller joined the Wellcome Trust as an executive board member for Science Funding and worked as an independent consultant.
Dr. Fuller received a B.Sc. in Immunology from University College London, his MB BS (MD) from St. Georges Hospital Medical School London and his MD (Ph.D.) from the University of London.
PAUL J. ATKINS, Ph.D.
President & Chief Operating Officer
Dr. Atkins co-founded Oriel Therapeutics Inc. in 2002. Prior to starting Oriel, he spent more than ten years with GlaxoSmithKline where he held various commercial strategy, global project management and product development roles, primarily of inhalation products. During his career Dr. Atkins worked in both the United Kingdom and the USA including positions with Upjohn (Pfizer) and Fisons (sanofi-aventis) before joining Glaxo in 1991 where he established the Inhaled Product Development group and was responsible for a number of global technical development programs, including the development of HFA metered dose inhalers and novel dry powder inhalers.
Dr. Atkins earned his Ph.D. from the University of London. He is internationally recognized as an expert in the inhaled product development area and has been a member MTOC since 1996 and an advisor/consultant to both UNEP and UNDP since 2002. He is the recipient of the 2008 EPA Stratospheric Ozone Protection Award.
DAN M. DEATON
Director of Product Development
Mr. Deaton formerly managed Biomedical Engineering at Kos Pharmaceuticals (acquired by Abbott in 2006), developing a wide range of innovative devices for pulmonary and nasal delivery. Prior to his tenure at Kos he held key engineering roles with two successful start-up ventures in medical imaging and manufacturing technology.
Mr. Deaton holds a Masters of Science in Mechanical Engineering from North Carolina State University and an MBA from Kenan-Flagler Business School at UNC Chapel Hill.
CHARLES E. MADER, Ph.D.
Director of Analytical and Formulation Development
Dr. Mader joined Oriel Therapeutics Inc. from GlaxoSmithKline where over the course of his 21-year tenure he held various global strategic and technical leadership positions in pharmaceutical development and manufacturing, including Director of US Inhaled Product Development.
Dr. Mader received his Ph.D. in Physical Chemistry from Duke University and served as a Post-Doctoral Fellow with Burroughs Wellcome Co.
MALINDA V. LONGPHRE, Ph.D.
Director of Clinical Trials Operations
Dr. Longphre joined Oriel Therapeutics Inc. from Aerovance where she spent four years managing phase I and II clinical trials for drug development in the areas of asthma, COPD, CF, and eczema, most recently as Director, Clinical. Prior to Aerovance, Malinda worked as a Group Head at the Bayer Corporation. Prior to Bayer, she was a Research Investigator for Bristol-Myers Squibb Pharmaceutical Research Institute.
Malinda received her BA and MA in Biology from the University of North Carolina at Greensboro. She received her Ph.D. in Environmental Health Sciences, in the Pulmonary Physiology Division, Johns Hopkins University, and served a Post-doctoral Fellowship, Cardiovascular Research Institute and Anatomy, at the University of California San Francisco.
JOHN MORGAN, Ph.D.
Vice President of Regulatory Affairs
Dr. Morgan joins Oriel with more than 20 years of experience in the health care industry. He was Vice President of Clinical and Regulatory Affairs at Ventaira Pharmaceuticals where he was responsible for clinical and regulatory activities in support of oral, inhaled product technologies. Prior to Ventaira, John held several key positions at GlaxoSmithKline where he was responsible for IND and NDA submissions for oral, inhaled MDI and DPI drug products.
Prior to GlaxoSmithKline, John was at Proctor & Gamble Pharmaceuticals where he was responsible for regulatory strategies and submissions for prescription drug products.
ELISE BURMEISTER-GETZ, Ph.D.
Associate Director of Clinical Pharmacology
Dr. Burmeister-Getz joined Oriel Therapeutics Inc. from Aerovance where she was Associate Director, Pharmacokinetics & Biostatistics. Prior to Aerovance, Elise spent more than 7 years performing scientific research in Pharmacokinetics & Bioanalytics at the Bayer Corporation.
Elise received her BS in Bioengineering from the University of Iowa. She received her Ph.D. in Bioengineering form the University of California at Berkeley and was awarded a President’s Postdoctoral Fellowship at the University of California, San Francisco in the Department of Biochemistry and Biophysics.
TERRY A. PAIT
Associate Director of Quality Assurance
Ms. Pait comes to Oriel with over 25 years of comprehensive experience in Quality Systems, Quality Assurance and Quality Compliance processes in a cGMP biologics and small molecule manufacturing environment. Prior to joining Oriel, Ms. Pait was Associate Director of QA Compliance with KBI BioPharma. Prior to KBI BioPharma, Terry spent more than twenty years with GlaxoSmithKline (formerly Glaxo Wellcome) where she held increasingly responsible roles in Lab Operations, Quality Control and Quality Systems.
Terry received her BS in Chemistry from North Carolina State University.
about us - board of directors
|
